Connor Clark & Lunn Investment Management Ltd. Grows Stake in Eli Lilly and Company $LLY

Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 23.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,073 shares of the company’s stock after purchasing an additional 8,055 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Eli Lilly and Company were worth $32,797,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. Willner & Heller LLC boosted its stake in Eli Lilly and Company by 1.5% during the first quarter. Willner & Heller LLC now owns 854 shares of the company’s stock worth $705,000 after buying an additional 13 shares during the period. Braun Bostich & Associates Inc. lifted its holdings in shares of Eli Lilly and Company by 2.5% in the 2nd quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock worth $411,000 after acquiring an additional 13 shares during the last quarter. Rise Advisors LLC boosted its stake in shares of Eli Lilly and Company by 1.8% during the 2nd quarter. Rise Advisors LLC now owns 732 shares of the company’s stock worth $571,000 after purchasing an additional 13 shares during the period. Occidental Asset Management LLC grew its holdings in Eli Lilly and Company by 0.7% during the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock valued at $1,533,000 after purchasing an additional 13 shares during the last quarter. Finally, New Insight Wealth Advisors raised its position in Eli Lilly and Company by 3.4% in the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock worth $307,000 after purchasing an additional 13 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

NYSE LLY opened at $923.35 on Monday. The firm’s fifty day simple moving average is $799.97 and its two-hundred day simple moving average is $775.01. The firm has a market capitalization of $872.92 billion, a P/E ratio of 60.35, a P/E/G ratio of 1.21 and a beta of 0.43. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $955.46.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter last year, the firm earned $1.18 EPS. The business’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Morgan Stanley dropped their price objective on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a report on Friday, October 3rd. Deutsche Bank Aktiengesellschaft reduced their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. UBS Group boosted their target price on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the company a “buy” rating in a research note on Friday. Finally, BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $960.88.

Insider Activity at Eli Lilly and Company

In related news, EVP Daniel Skovronsky bought 1,000 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the transaction, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David A. Ricks purchased 1,632 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 4,314 shares of company stock valued at $2,766,929 over the last 90 days. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.